Skip to search formSkip to main contentSkip to account menu

darexaban

Known as: N-(2-hydroxy-6-(4-methoxybenzamido)phenyl)-4-(4-methyl-1,4-diazepan-1-yl)benzamide 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

AzepinesBenzamidesFactor Xa inhibitors

Narrower (1)

YM 150

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
An Update on Novel Antiplatelets in Vascular Patients.
BACKGROUND Acetylsalicylic acid, clopidogrel and cilostazol are well-established agents inhibiting the normal function of… 
2017
2017
Une ou deux fois par jour : quel est le meilleur schéma posologique pour les anticoagulants oraux directs ?
2014
2014
Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates.
2013
2013
Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin
To investigate the impact of the direct Factor Xa inhibitor darexaban administered in a modified-release formulation (darexaban… 
Review
2013
Review
2013
Investigational anticoagulants for hematological conditions: a new generation of therapies
Introduction: The introduction of novel anticoagulants has had contrasting effects on the agents in the pipeline, fueling the… 
2012
2012
Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label study.
Review
2012
Review
2012
Novel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants?
Thrombosis plays a key role in the pathophysiology of acute coronary syndromes (ACS). The management of patients with ACS… 
Review
2012
Review
2012
New oral anticoagulant agents after ACS
Despite tremendous progress in the management of patients with an acute coronary syndrome (ACS), morbidity and mortality remains… 
Review
2012
Review
2012
Oral IIa and Xa inhibitors for prevention of stroke in atrial fibrillation: clinical studies and regulatory considerations.
Atrial fibrillation (AF), the most common, clinically significant, cardiac arrhythmia affects 1% of the general population and… 
Review
2011
Review
2011
[Current status and future of anti-Xa inhibitors].
Anticoagulant therapy, known as warfarin, has been underused despite its marked benefit from embolic prevention. The intricate… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)